Status:
COMPLETED
Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone.
Lead Sponsor:
Technische Universität Dresden
Conditions:
Healthy Subjects
Eligibility:
MALE
18-40 years
Phase:
NA
Brief Summary
The study is designed to test the hypothesis in healthy subjects that the oral antidiabetic drug rosiglitazone provides additional vascular relaxing or modulating effects in addition to its blood gluc...
Detailed Description
The aim of the study is to investigate the effect of oral rosiglitazone therapy on the vascular responsiveness of different vasoactive compounds (angiotensin II, insulin, histamine and glyceroltrinitr...
Eligibility Criteria
Inclusion
- Male
- Healthy
- 18 - 40 years old
- Non-smoker
- No additional medication
Exclusion
- Any relevant disease
- Smokers
- Elevated liver enzymes
- Body weight different from Broca norm \> 20%
- Allergies
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00154011
Start Date
September 1 2005
End Date
June 1 2006
Last Update
September 12 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Clinical Pharmacology
Dresden, Germany, 01307